OMEICOS Therapeutics, a spin-off from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), announced the first closing of a Series B financing round with EUR 8.3 million. The funding comes from OMEICOS’ existing investor consortium, which also includes Ascenion.
In addition, the company has enrolled the first subject in its first-in-man clinical study with its lead candidate OMT-28. The compound is a stable synthetic small molecule analogue of a natural omega-3 fatty acid metabolite and has proven its anti-arrhythmic and cardioprotective potential in different in vivo models. Clinical development currently focuses on atrial fibrillation, the most common cardiac arrhythmia in humans. It affects over 30 million patients worldwide, and the number is rising by 2% per year due to the aging population.
For study details and further information see:
OMEICOS press release